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DNA damage response mediator protein 53BP1 is a key regulator of non-homologous end-joining (NHEJ) repair.
53BP1 protects DNA broken ends from resection by recruiting two downstream factors, RIF1 (RAP1-interacting factor 1)
and PTIP (Pax transactivation domain-interacting protein), to double-stranded breaks (DSBs) via ATM (ataxia
telangiectasia mutated)-mediated 53BP1 phosphorylation, and competes with BRCA1-mediated homologous recombination
(HR) repair in G1 phase. In contrast, BRCA1 antagonizes 53BP1-direct NHEJ repair in S/G2 phases. We and others have
found that BRCA1 prevents the translocation of RIF1 to DSBs in S/G2 phases; however, the underlying mechanism remains
unclear. Here we show that efficient ATM-dependent 53BP1 phosphorylation is restricted to the G1 phase of the cell cycle,
as a consequence RIF1 and PTIP accumulation at DSB sites only occur in G1 phase. Mechanistically, both BRCT and
RING domains of BRCA1 are required for the inhibition of 53BP1 phosphorylation in S and G2 phases. Thus, our findings
reveal how BRCA1 antagonizes 53BP1 signaling to ensure that HR repair is the dominant repair pathway in S/G2 phases.
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Introduction
DNA double-stranded breaks (DSBs) arise from
many sources, including exposure to ionizing radiation,
reactive oxygen species and collapse of replication forks.
DSBs must be repaired properly to ensure genomic sta-
bility. There are twomajor pathways for repairingDSBs:
homologous recombination (HR) and non-homologous
end joining (NHEJ). DNA repair mechanisms differ at
different stages of the cell cycle. In S and G2 phases, cells
use HR repair to rejoin DNA breaks when homolog
sequences on the sister chromatid are present. In G1
phase, as the sister chromatid is absent, NHEJ is the
major pathway for DSB repair. The choice of DSB
repair by HR or NHEJ is also dictated by the 5ʹ–3ʹ DNA
end resection at break sites; extensive end degradation is
an essential step inHR, whereas NHEJ can only occur at
DNA ends with limited or no processing.
BRCA1 (breast cancer 1, early onset) is a well-
known tumor suppressor that has a critical role in
DNA repair. BRCA1 harbors a highly conserved
amino terminal RING domain and tandem BRCT
domains at its carboxyl terminus. BRCT domains are
phosphopeptide recognition modules that participate
in the assembly of protein complexes required for
DNA repair functions. The RING domain of BRCA1
confers E3 ubiquitin ligase activity to BRCA1 via its
ability to interact with ubiquitin-conjugating enzymes
(E2) and BARD1 [1]. The major cause of the genetic
instability associated with BRCA1 deficiency is the
impaired ability of BRCA1 mutant cells to undergo
HR-mediated DSB repair. This inability forces cells
to rely on alternative non-template-based repair path-
ways, such as NHEJ, which could result in chromo-
some aberrations and/or translocation. BRCA1 seems
to act at multiple stages during HR, as BRCA1
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facilitates both early (DNA end resection and single-
stranded DNA (ssDNA) formation) and late (RAD51-
mediated DNA strand exchange) phases of HR.
At present, the precise mechanisms by which BRCA1
functions in HR remain unclear, but the antagonistic
relationship between BRCA1 and another DNA repair
protein, 53BP1 (p53- binding protein 1), during DNA
repair pathway choice have been well established in
recent years. 53BP1 is a key positive regulator of NHEJ-
mediated DSB repair and protects broken DNA ends
from processing, a process that is promoted by BRCA1
[2, 3]. Both the physical presence of 53BP1 at DSBs and
the phosphorylation of 53BP1 by ATM (ataxia tel-
angiectasia mutated) kinase are required for the anti-HR
activities of 53BP1 [4]. We and other researchers have
found that ATM-phosphorylated 53BP1 recruits a
mediator protein, RIF1 (RAP1-interacting factor 1) to
DNA damage sites to protect broken DNA ends from
BRCA1-mediated end resection and subsequent HR
repair [5–8]. PTIP (Pax transactivation domain-
interacting protein) was discovered as another
phospho-53BP1 binding protein that is also required
for 53BP1-mediated inhibition of BRCA1-directed HR
and the sensitivity to poly ADP ribose polymerase
(PARP) inhibitor in BRCA1 mutation cancer cells [9].
Therefore, 53BP1 acts as a scaffold protein to recruit
two downstream effectors, RIF1 and PTIP, at DSBs to
inhibit HR and directs DNA repair toward NHEJ. On
the other hand, 53BP1’s NHEJ-promoting function is
also inhibited by BRCA1, as loss of BRCA1 enables
the accumulation of RIF1 at DSBs in S/G2 phase cells
and inhibits initial resection of DNA ends [5, 6, 10].
The available evidence clearly shows that the
balance of BRCA1 and 53BP1 controls the choice of
DNA repair pathways, and that this balance is cell
cycle regulated. However, essentially nothing is known
about the mechanism by which BRCA1 suppresses
53BP1 pathway in S/G2 phases. Here, using synchro-
nized cells, we found that BRCA1 inhibits the phos-
phorylation of 53BP1 by ATM and therefore prevents
the subsequent accumulation of RIF1 and PTIP at
DSB sites in S/G2 phases of cell cycle. Thus, the
53BP1-initiated NHEJ repair is confined in G1 phase.
Results
Opposite regulations of DSB-induced foci formation
between PTIP and BRCA1
We and others have demonstrated that BRCA1 and
RIF1 display mutually exclusive foci formation in
response to ionizing radiation (IR) [5, 6, 11]. Because
the accumulation of PTIP, another 53BP1 downstream
effector, at DSB sites is also ATM- and 53BP1-
dependent but RIF1-independent [9], we decided to
investigate the potential cell cycle-dependent regulation
of PTIP localization at DSBs. We generated a PTIP
polyclonal antibody that was highly specific for western
blotting and immunofluorescence staining. The poly-
clonal antibody only recognized a band of ~ 130 kDa
(PTIP-predicated molecular weight: 121 kDa) and the
band was undetectable in PTIP knockout cells gener-
ated using CRISPR/Cas9 system (Supplementary
Figure S1a). Using this antibody for immunostaining,
we found that PTIP is a pan-nuclear protein in unda-
maged HeLa cells and form foci after exposure to γ-
irradiation. In addition, the foci formation of PTIP
were 53BP1 and ATM dependent (Supplementary
Figure S1b), as previously reported [9]. Strikingly,
although 53BP1 foci formed in over 90% of the dividing
cells, only ~ 60% of cells showed discernible PTIP foci
formation (Figure 1a). When we co-stained these cells
with BRCA1 and PTIP antibodies, we found that PTIP
and BRCA1 showed mutually exclusive foci formation
(Figure 1a). Cells co-stained with S and G2 cell cycle
marker cyclin A further supported that PTIP foci were
absent in S/G2 cells, and this phenomenon was also
observed in other cell lines including non-tumorigenic
breast epithelial cell line MCF10A (Supplementary
Figure S1c). On the contrary, 53BP1 foci formation
and ATM activation occurred in all phases of the cell
cycle, whereas BRCA1 only translocated toDSBs in the
S/G2 phases of cells (Figure 1b), as previously reported
[5]. We also utilized laser-induced microirradiation to
generate DSBs, and similar results were obtained. PTIP
failed to be recruited to laser-induced DNA damage sites
where strong BRCA1 strips formed and vice versa
(Supplementary Figure S2). To further elucidate the cell
cycle dependency of PTIP foci formation, we synchro-
nized the cells in G1 or S/G2 phases and then treated
with irradiation. The results showed that, as with RIF1,
PTIP only translocates to DSB sites in G1 phase, but not
in S/G2 phases, which is opposite to that of BRCA1
(Figures 1c and d). The diminished foci formation of
PTIP and RIF1 in the S/G2 phases was not attributable
to defective ATM activation, as ATM autopho-
sphorylation on Ser1981 occurred in all stages of the cell
cycle (Figures 1b and c). Together, these data indicate
that the accumulation of PTIP at DSB sites is similar to
RIF1, which only occurs in G1 cells.
ATM-dependent 53BP1 phosphorylation is G1 phase
specific
As PTIP and RIF1 share the same mechanism
for their translocation to DSBs (that is, binding to
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ATM-phosphorylated 53BP1), we next asked whether
the level of 53BP1 phosphorylation would change in
different phases of cell cycle in response to IR. We used
two commercially available antibodies that recognize
ATM phosphorylation sites on 53BP1: anti-S25/29 and
anti-S1778 antibodies. These two phospho-antibodies
specifically recognize the phosphorylated forms of
53BP1 because the stainings were induced by IR and
were undetectable in 53BP1 knockout cells generated
using CRISPR/Cas9 technology (Supplementary
Figure S3a). In addition, phosphorylation on these
S/TQ sites were ATM dependent, as ATM inhibitor
KU55933, but not DNA-PK inhibitor NU7026, effi-
ciently abolished IR-induced 53BP1 phosphorylation
at S25/29 and S1778 sites (Supplementary Figure S3b).
Immunostaining with these two phospho-53BP1 anti-
bodies revealed that not all 53BP1 foci-positive
cells exhibited positive 53BP1 phosphorylation after
irradiation, and the signal of 53BP1 phosphorylation
was greatly diminished in BRCA1-positive cells (that
is, cells in the S/G2 phases). Similarly, IR-induced
replication protein A (RPA) foci formed only in cells
that did not exhibit p-53BP1 staining (Figure 2a).
These data suggest that DNA damage-induced 53BP1
phosphorylation mainly occurs in G1 cells. The G1-
specific phosphorylation of 53BP1 by ATM is unique
because ATM autophosphorylation on Ser1981
occurred in all phases of the cell cycle regardless of
BRCA1 status (Figures 1b and c, and 2b). Moreover,
we tested other ATM substrates. Immunostaining with
Figure 1 Cell cycle-dependent PTIP (Pax transactivation domain-interacting protein) foci formation. (a) Asynchronous HeLa cells
were treated with γ-irradiation (ionizing radiation (IR), 10 Gy) and recovered for 4 h before fixation and stained with antibodies as
indicated. Asterisks indicate PTIP foci-negative cells. (b) Asynchronous HeLa cells were treated as in a and co-stained with S
phase marker, cyclin A. G1 phase cells were indicated. (c) Representative images showing PTIP, RIF1 (RAP1-interacting
factor 1) and BRCA1 foci. HeLa cells were enriched in G1 phase by treating with nocodazole and then released for 6 h. S/G2
phase cells were enriched by double-thymidine block and released for 6 h. Two hours before fixation, cells were irradiated with
10 Gy of IR. (d) A histogram showing the percentage of cells containing 410 nuclear foci. Experiments were performed in
triplicate and at least 100 cells were counted in each experiment for each treatment.
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pan-ATM substrates antibody, which recognizes the
S*/T*Q motif [12], also suggested that the phosphor-
ylation of ATM substrates occur in all cell cycle phases
(Supplementary Figure S4). Similarly, γH2AX and
KAP-1 were phosphorylated throughout the cell cycle
(Supplementary Figure S4). However, phosphoryla-
tion of NBS1 coincided with BRCA1 foci formation
(Supplementary Figure S4), indicating that NBS1 may
be phosphorylated by both ATM and Ataxia tel-
angiectasia and Rad3-related protein (ATR) in S/G2
cells. The cell cycle-dependent foci formation of these
DNA repair proteins are summarized in Figure 2c.
To confirm these results and ensure that the inverse
correlation between phospho-53BP1 and BRCA1 was
Figure 2 Cell cycle-dependent 53BP1 phosphorylation by ATM (ataxia telangiectasia mutated). (a) Asynchronous HeLa cells
were treated as described in Figure 1a, arrows indicate p-53BP1 foci-negative cells. Cells with 410 foci following ionizing
radiation (IR) were counted as positive cells. (b) HeLa cells were processed as in a, and the asterisks indicate BRCA1 or p-53BP1
foci-negative cells. The percentage of asynchronous cells forming indicated foci were as follows: S25/S29 (58%), S1778 (60%),
53BP1 (98%), BRCA1 (65%), RPA2 (52%) and p-ATM (94%), at least 200 cells were counted. (c) Summary of cell
cycle-dependent foci formation of BRCA1 and 53BP1 complexes. (d) HeLa cells were arrested in M phase with nocodazole
(100 ngml− 1) treatment for 16 h and then released for different time periods. The cells were irradiated with 10 Gy of IR 1 h or left
untreated before harvesting.
Cell cycle-dependent inhibition of 53BP1 signaling
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not resulting from cell cycle-dependent changes in pro-
tein levels, we examined IR-induced 53BP1 phosphor-
ylation in synchronized cells. HeLa cells were arrested in
mitosis by nocodazole treatment, released into G1, S and
G2 phases, and were irradiated or left untreated. 53BP1
phosphorylation peaked in G1 phase and then quickly
decreased after cells entered S and G2 phases—as judged
by cyclin A levels. Consistently, ATM was activated
regardless of cell cycle stages. The expression of 53BP1
complex (that is, 53BP1, PTIP and RIF1) did not change
appreciably throughout the cell cycle, only RIF1 showed
a reduction in mitosis. BRCA1 level was low in G1
phase, increased when cells enter S phase and reached the
maximum in G2 phase, and IR treatment induced
phosphorylation of BRCA1 during S and G2 phases, as
indicated by mobility shift. In contrast to 53BP1 phos-
phorylation, CHK1 phosphorylation was only observed
in S and G2 cells (Figure 2d), which was consistent with
the report that ATR activation is restricted to S/G2
phases [13]. Taking together, our data indicate that
Figure 3 BRCA1 inhibits 53BP1 phosphorylation. (a) BRCA1 deficiency restored PTIP (Pax transactivation domain-interacting
protein) and p-53BP1 foci formation in S/G2 phase cells. HeLa cells infected with lentivirus carrying non-target or BRCA1 short
hairpin RNAs were synchronized in S/G2 and irradiated as described in Figure 1c. (b) Quantification of 53BP1 complex foci
formation, the data are represented as the mean± s.e. (n = 3). More than 100 cells were counted to determine the percentages of
foci forming cells in each sample. (c) Depletion of BRCA1 increases 53BP1 phosphorylation by ATM (ataxia telangiectasia
mutated). Control and BRCA1 knockdown cells were synchronized in S/G2 phases as described in Figure 1c. Cells were
mocked-treated or treated with ionizing radiation. One hour after ionizing radiation, cells were harvested, and the cell lysates were
analyzed by immunoblotting using the indicated antibodies. (d) ATM kinase assays were performed with anti-ATM
immunoprecipitates prepared from control (Con.) or BRCA1-depleted cells. ATM kinase was incubated with the purified
GST-53BP1 fusion protein (1–910 aa) for the times as indicated. The phosphospecific antibody against phospho-Ser25 and
Ser29 of 53BP1 was used for western blotting to detect phosphorylated 53BP1. IR, ionizing radiation; shRNA, short hairpin RNA.
Lin Feng et al.
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effective ATM-induced 53BP1 phosphorylation is lim-
ited to G1 phase.
Recovered 53BP1 phosphorylation, PTIP and RIF1 foci
formation in S/G2 cells by BRCA1 deficiency
Loss of BRCA1 restored RIF1 re-localization to
DSBs in S/G2 phase cells [5, 6, 10]. As the cell cycle-
specific foci formation of PTIP and p-53BP1 resembled
that of RIF1 (Figures 1 and 2), we investigated whether
DSBs accumulation of PTIP and p-53BP1 were also
affected by the BRCA1 status. HeLa cells infected with
control or BRCA1 short hairpin RNAs were
synchronized in the S/G2 phases by double-thymidine
block. Immunofluorescence data showed that
ablation of BRCA1 fully restored PTIP and p-53BP1
accumulation at DSBs (Figure 3a and b). Western blot
results also indicated that BRCA1 depletion increased
53BP1 phosphorylation levels in S/G2 cells. As expec-
ted, CHK1 phosphorylation, an indicator for DNA
end resection and ssDNA formation [14], was greatly
reduced by BRCA1 deficiency. Consistent with
immunostaining results, ATM autophosphorylation
was not affected by BRCA1 loss.
We also examined other known ATM substrates
such as SMC1, CHK2, KAP-1 and NBS1. The phos-
phorylation levels of SMC1, CHK2 and KAP-1 were
not affected by BRCA1 deficiency. The only exception
was NBS1, phosphorylation of which is S/G2 specific
(Supplementary Figure S4) and declined in the absence
of BRCA1 (Figure 3c). The specific mechanism by
which BRCA1 stimulates NBS1 phosphorylation is
currently unknown, but the cell cycle-dependent
complex formation of BRCA1 and NBS1 might
contribute to this regulation [15]. An alternative
explanation for the regulation could be that NBS1 is
also a substrate of ATR [16], which is activated
following IR in a BRCA1-dependent manner [17].
To further exclude the possibility that BRCA1
directly regulates ATM kinase activity, we generated
GST-53BP1 fusion protein (1–910 aa) that contains
multiple ATM phosphorylation sites (S/TQ sites) as
substrates and co-incubated with endogenous ATM
kinase that was immunoprecipitated from normal or
BRCA1-deficient cells. The in vitro kinase assay results
suggest that ATM immunoprecipitates prepared from
control or BRCA1-deficient cells were capable of
phosphorylating recombinant 53BP1 to similar extent
(Figure 3d). Thus, BRCA1 likely inhibits 53BP1
phosphorylation in vivo without affecting ATM
activation and/or ATM kinase activity.
We next investigated whether the restored 53BP1
phosphorylation and PTIP foci formation are direct
results of BRCA1 deficiency or are indirectly mediated
by DNA end resection defect accompanied with
BRCA1 loss. Because CtBP-interacting protein (CtIP)
is a BRCA1-associated protein that participates in
DNA end processing [18, 19], we depleted CtIP and
synchronized the cells in the S/G2 phases. Immunos-
taining data suggested that CtIP has only a minimal
role in antagonizing 53BP1 signaling because few PTIP
and p-53BP1 foci formation were observed in S/G2
phases of cells lacking CtIP (Supplementary Figure
S5a); however, severe resection defects occurred in
both CtIP- and BRCA1-depleted cells (Supplementary
Figure S5b). These observations are consistent with our
previous results on RIF1 [5]. Therefore, hyper-
activation of DNA end resection machinery in S and
G2 phases does not in itself cause a defect in 53BP1
signaling.
Both BRCT and RING domains of BRCA1 are required
for 53BP1 inhibition
Next, we investigated the mechanism by which
BRCA1 inhibits 53BP1 phosphorylation. Mass
spectrometry analysis results of tandem affinity puri-
fication of BRCA1 and BARD1 complexes identified
53BP1 as a BRCA1-binding protein (Supplementary
Figure S6a). Reciprocal co-immunoprecipitation
experiments of endogenous BRCA1 and 53BP1 also
confirmed the physical interaction between BRCA1
and 53BP1; however, the binding was not affected by
IR (Figure 4a). Because BRCA1 and 53BP1 participate
in opposite repair pathways and the only known
enzymatic function of BRCA1 is its E3 ubiquitin ligase
activity, which is mediated by the N-terminal RING
domain of BRCA1, we tested whether BRCA1 could
ubiquitinate 53BP1 in vivo. Co-overexpression of
53BP1 with wild-type BRCA1 induced robust ubiqui-
tination of 53BP1; however, co-transfection with a
BRCA1 C61G mutant, which included a mutation in
the RING domain targeting the critical Zn2+-chelating
residue, resulted in reduction of 53BP1 ubiquitination
(Figure 4b). Furthermore, the ubiquitination of
endogenous 53BP1 was greatly reduced in cells deple-
ted of BRCA1, while IR treatment led to slightly
increased 53BP1 ubiquitination (Figure 4c). We sear-
ched for the regions on 53BP1 that could be ubiquiti-
nated by BRCA1. In vitro ubiquitination assays
revealed that several regions at the C terminus of
53BP1 could be ubiquitinated by BRCA1/BARD1
complex (Supplementary Figure S6b), indicating that
BRCA1 may ubiquitinate multiple residues on the C
terminus of 53BP1. However, so far, we could not
identify the BRCA1-dependent ubiquitination sites on
Cell cycle-dependent inhibition of 53BP1 signaling
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53BP1. Thus, we could not conclude whether or not
BRCA1-dependent ubiquitination of 53BP1 has any
role in BRCA1-mediated suppression of 53BP1 phos-
phorylation and function.
Instead, we re-introduced several BRCA1 mutants to
BRCA1-depleted cells and examined PTIP foci forma-
tion in cells synchronized in the S/G2 phases. Wild-type
BRCA1 suppressed PTIP localization to DSBs, whereas
the C61G mutant, as well as M1775R (a BRCT domain
mutant that abolishes phospho-protein binding activity
and DSB accumulation ability of BRCA1), behaved
similar to loss-of-function mutants and failed to suppress
PTIP foci formation in S/G2 cells (Figures 4d and e). The
I26A mutant, which is a synthetic RING mutant that
ablates the interaction of BRCA1 with all of the known
cognate E2 enzymes in vitro [20, 21] only showed modest
inhibition of PTIP foci formation when compared with
the C61G mutant (Figures 4d and e). We speculate that
the synthetic I26A mutant may be a hypomorphic
mutant that still possesses residual activity in vivo.
Alternatively, the intact RING domain, and/or the
BRCT domain of BRCA1, may mediate the association
of BRCA1 with another uncharacterized E3 ubiquitin
ligase that is the bona fide E3 for 53BP1, or these
domains may also mediate other protein–protein inter-
actions that could prevent 53BP1 phosphorylation
independent of its ubiquitination status. In summary,
BRCA1 likely inhibits 53BP1 signaling through its
RING and BRCT domains (Figure 5); however, the
detailed mechanisms remain unclear.
Figure 4 The E3 ubiquitin ligase activity of BRCA1 is required for inhibition of 53BP1 signaling. (a) 293T cells were untreated or
irradiated at 10 Gy and processed 1h later. Cell lysates were prepared and immunoprecipitated (IP) using rabbit immunoglobulin
G (IgG) or anti-53BP1 antibody. (b) BRCA1 ubiquitinates 53BP1 in vivo. 293T cells were transfected with His-ubiquitin (Ub), SFB-
BRCA1/BARD1 and HA-53BP1. The pull-down and immunoblotting analysis was conducted as indicated. (c) HeLa cells infected
with lentivirus carrying control or BRCA1 short hairpin RNAs were irradiated or untreated. Total cell lysates were prepared.
Immunoprecipitation using high-salt buffer was performed with normal rabbit IgG or anti-53BP1 antibody. Endogenous 53BP1
ubiquitination was detected with anti-Ub antibody (see Materials and Methods for details). (d) BRCA1-depleted HeLa cells were
transfected with various BRCA1 constructs, synchronized in S/G2 phases and processed as described in Figure 1c.
(e) Quantification of PTIP (Pax transactivation domain-interacting protein) foci formation by the indicated BRCA1 constructs,
as described in c. More than 30 FLAG-positive cells and the cells with420 PTIP foci were counted, results are presented as the
means (± s.d.) of three independent experiments. Ni-NTA, nickel-nitrilotriacetic acid; WT, wild type.
Lin Feng et al.
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Discussion
Our findings reveal mechanistically how BRCA1
controls repair pathway choice and may provide a
novel diagnosis marker for cancer patients with a
BRCA1 mutation. We demonstrate that BRCA1
restrains 53BP1 phosphorylation in the S/G2 phases to
ensure the repair of DSBs by HR. On the other hand,
53BP1 inhibits HR and facilitates NHEJ by recruiting
two downstream proteins to DSBs in an ATM-
dependent manner [5–9, 11]. Previous studies on
RIF1 have revealed the G1 phase-specific translocation
of RIF1 to the DSB sites and the antagonizing role of
BRCA1 for RIF1 foci formation in the S/G2 phases
[5, 6, 10]. However, the mechanism by which BRCA1
competes with RIF1 and prevents RIF1’s localization
to DSB sites in the S/G2 phases was unknown.
PTIP is another downstream effector of 53BP1 [9],
but the foci formation of endogenous PTIP in different
cell cycle phases had not been determined owing to a
lack of antibodies that were suitable for detecting
endogenous PTIP foci [9]. After creating a suitable
PTIP antibody, we found that PTIP had the same cell
cycle-dependent foci formation as RIF1, as revealed
by both conventional microscope and laser-induced
microirradiation (Figure 1 and Supplementary
Figure S2), which prompted us to trace the upstream
events that mediate the translocation of RIF1 and
PTIP to the DSBs. Proper DSB localization and
ATM-dependent phosphorylation of 53BP1 are
required for RIF1 and PTIP foci formation. As 53BP1
forms foci in almost all cell cycle phases, we focused on
ATM-mediated phosphorylation of 53BP1 in different
cell cycle stages, and found that ATM-mediated 53BP1
phosphorylation occurs predominantly in G1 cells
(Figure 2). These observations were contrary to a
previous report, which did not detect cell cycle-
dependent p-53BP1 foci formation [22]. The reason
for this discrepancy is unknown. However, we showed
here the cell cycle-dependent p-53BP1 in a large
population of asynchronized cells (Figures 2a and b)
and in synchronized cells (Figure 2d). Moreover, these
data agree with the RIF1 and PTIP localization,
which depends on 53BP1 phosphorylation. Strikingly,
depletion of BRCA1 enables 53BP1 phosphorylation
to occur in S/G2 phase cells, and subsequently, RIF1
and PTIP accumulate at the DSBs in the S/G2 phases
(Figure 3) to inhibit DNA end processing and HR
repair even in the presence of the homology template.
Mechanistically, BRCA1 does not attenuate ATM
activation, as many ATM substrates are equally
phosophorylated in cells with or without BRCA1.
Unlike 53BP1, these ATM substrates did not
show G1-specific phosphorylation (Figure 3c and
Supplementary Figure S4). Moreover, the extent of
DNA end resection is also not the determining factor
for ATM-dependent 53BP1 phosphorylation, as CtIP
depletion results in the same severe DNA end resection
defects as does BRCA1 depletion, but fails to fully
restore 53BP1 signaling in S/G2 cells (Supplementary
Figures S5a and b). In addition, we also found that
although depletion of 53BP1 largely restored CHK1
phosphorylation in response to camptothecin in
BRCA1-deficient cells; however, the phosphorylation
of RPA was not efficiently restored (Supplementary
Figure S5c). CHK1 phosphorylation is a sensor for
Figure 5 A working model for an inhibitory role of BRCA1 in the regulation of 53BP1 signaling.
Cell cycle-dependent inhibition of 53BP1 signaling
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ssDNA–dsDNA junctions, whereas RPA phosphor-
ylation levels reflect the length of ssDNA [23]. Together
with previous studies on 53BP1/RIF and BRCA1, we
propose that 53BP1 protects the double-stranded DNA
from initial resection, which is mediated by BRCA1.
However, once resection starts and the long stretches of
ssDNA are being generated, 53BP1 complex can no
longer protect them from processing. The reduced
p-RPA in 53BP1/BRCA1 double-knockout (KO) cells
may be due to additional functions of BRCA1 in DNA
end resection. For example, a recent study indicates
that the full activation of CtIP require its interaction
with BRCA1 [24]. We hypothesize that BRCA1 may
act both in early and late stages of DNA end resection,
the former is achieved by antagonizing 53BP1, the
latter may be mediated through CtIP interaction and
activation. Of course, additional studies are needed to
fully address this question.
53BP1 is present in BRCA1 complexes
(Supplementary Figure S6a), a finding that is sup-
ported by previous report [25]. Moreover, we showed
that BRCA1 ubiquitinates 53BP1, and that the C61G
RING mutant fails to ubiquitinate 53BP1 efficiently.
More important, reconstitution of the C61G mutant
into BRCA1-deficient cells in the S/G2 phases was
unable to suppress PTIP foci formation, implying that
the E3 ligase activity of BRCA1 may be important for
inhibiting 53BP1 phosphorylation. However, another
BRCA1 RING mutant, I26A, seems to still preserve
some ability to inhibit 53BP1, as both the percentage of
PTIP foci-positive cells and the number of PTIP foci in
each nucleus were lower in cells reconstituted with the
I26A mutant than in cells reconstituted with the C61G
mutant. Nevertheless, the extent of inhibition by the
I26A mutant is milder than that of wild-type BRCA1
(Figure 4). These data support those of earlier studies
that used the C61G and the I26A knock-in mice
[26, 27]. It does not preclude the possibility that
mutation of the Zn2+-chelating cysteine may affect
local structural integrity of BRCA1 [22], which may
not only just affect the E3 ligase activity of BRCA1, or
the possibility that I26A still able to bind certain E2s,
especially the E2s responsible for ubiquitin chain
elongation [28].
We do not have enough evidence to support that
BRCA1 directly ubiquitinates 53BP1 and prevents
53BP1 phosphorylation. In vitro ubiquitination assays
showed that multiple regions of 53BP1 could be
ubiquitinated by BRCA1 (Supplementary Figure S6a),
which impede our attempts to map the ubiquitination
sites on 53BP1 and further dissect the roles of BRCA1-
mediated 53BP1 ubiquitination in DNA repair choice
and the prevention of 53BP1 phosphorylation and
functions. Thus, a direct role of BRCA1-dependent
ubiquitination events in preventing 53BP1 phosphor-
ylation remains unknown. It is possible that even
though BRCA1 could ubiquitinate 53BP1, its ability to
inhibit 53BP1 may be mediated by other BRCA1-
dependent events, which require both its RING and
BRCT domains.
We propose that in normal S/G2 cells, BRCA1 may
directly or indirectly preclude or reduce its phosphor-
ylation by ATM, although the detailed mechanisms
remain unknown. It is possible that the inhibition of
53BP1 phosphorylation subsequently prevent the
recruitment of RIF1 and PTIP to DSBs. The broken
DNA ends are therefore processed by nucleases
involved in resection. Once the long ssDNA regions are
generated, these broken DNA are destined for repair
by the high-fidelity HR process. However, in breast
and ovarian cancer cells with BRCA1 deficiency,
53BP1 signaling in the S/G2 phases is no longer
inhibited, and RIF1 and PTIP translocate to DNA
break sites via binding to phosphorylated 53BP1 to
protect DNA ends from processing. As a result, HR is
suppressed and the error-prone NHEJ takes over
(Figure 5), which may lead to the accumulation of
chromosome aberrations and eventually lead to
tumorigenesis.
The most promising strategy for treating
HR-deficient tumors, such as BRCA1-mutated breast
and ovarian cancers, is the use of PARP inhibitors [29].
Although a significant percentage of BRCA1 mutation
carriers responded to poly(ADP-ribose) polymerase
inhibitors (PARPi), some patients were resistant to this
treatment. Breast cancers arising in BRCA1 mutation
carriers frequently showed low levels of 53BP1
expression. Interestingly, a fraction of PARPi-resistant
tumors restored HR yet did not lose 53BP1 [30]. We
envision that 53BP1 hypo-phosphorylation and ATM
inactivation, along with the failure of RIF1 and PTIP
foci formation, may emerge as novel indicators for
PARPi resistance in BRCA1-mutated cancer patients.
Materials and Methods
Antibodies
The following antibodies were used in this study: anti-FLAG
(F3165, Sigma, St Louis, MO, USA); anti-BRCA1 (D-9, Santa
Cruz, Dallas, TX, USA); anti-cyclin A (sc-751 and sc-271645,
Santa Cruz); anti-NBS1 (A301-289A, Bethyl, Montgomery,
TX, USA); anti-53BP1(612522, BD, San Jose, CA, USA); anti-
phospho-ATM (S1981) (4526, Cell Signaling, Danvers, MA,
USA); anti-phospho-RPA32 (S4/S8) (A300-245, Bethyl); anti-
phospho-53BP1 (S25/29) (2674, Cell Signaling); anti-phospho-
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53BP1 (S1778) (2675, Cell Signaling); anti-phospho-NBS1 (S343)
(3001, Cell Signaling); anti-phospho-SMC1 (S957) (4801,
Cell Signaling) anti-phospho-CHK1 (S345) (2348, Cell Signal-
ing); anti-phospho-KAP-1 (S824) (4127, Cell Signaling) and
anti-phospho-(Ser/Thr) ATM/ATR substrate antibody (2851,
Cell Signaling). Rabbit anti-PTIP antisera were obtained from
rabbits immunized with GST-PTIP (residues 590–1 069) fusion
protein expressed and purified from Escherichia coli. Antisera
were affinity-purified using AminoLink Plus Immobilization
and Purification Kit (Pierce, Waltham, MA, USA ). Rabbit
polyclonal antibodies against BRCA1, RIF1, ATM,
γH2AX, 53BP1 and phospho-CHK2 (T68) were described
previously [5, 31–33].
Cell cycle synchronization
Synchronization methods were similar to those described
previously [5]. Cells were released from double-thymidine block
for 6 h to synchronize in S/G2 phases.
Cell culture, cell transfection, short hairpin RNAs and
fluorescence microscopy
The methods used to culture human cells, the sequences of
short hairpin RNAs, microscopy and laser-induced micro-
irradiation methods were described previously [5, 31].
Tandem affinity purification, immunoprecipitation, in vivo
and in vitro ubiquitination asssay
Tandem affinity purification were performed as described
previously [31]. As for immunoprecipitation assay, cells were
irradiated (10 Gy) or untreated and harvested 1 h later. Cells
were lysed in NETN buffer (20 mM Tris-HCl at pH 7.0, 100mM
NaCl, 1 mM EDTA and 0.5% Nonidet P-40) containing 50mM
β-glycerophosphate, 10 mMNaF and 1 μg ml− 1 each of pepstatin
A and aprotinin, and 5mM N-Ethylmaleimide (NEM). After
centrifugation, the supernatant (soluble fraction) were collected
and the pellet was sonicated in high-salt solution (20 mM Tris-
Hcl at pH 7.0, 0.5 MNaCl, 1 mM EDTA, 1mM EGTA, protease
and phosphatase inhibitor and 5 mM NEM) to extract
chromatin-bound protein fractions. The supernatants were
combined and centrifuged again at 14 000 r.p.m. to remove
debris and then subjected to immunoprecipitation. For ubiqui-
tination assay, the total lysates were immunoprecipitated with
normal rabbit immunoglobulin G or anti-53BP1 polyclonal
antibodies for 4–6 h at 4 °C. This was followed by incubating the
mixture with protein A/G agarose for an additional hour.
Immunoprecipitates were washed three times with high-salt
NETN buffer (20 mM Tris-HCl at pH 7.0, 500mM NaCl,
1 mM EDTA and 0.5% Nonidet P-40) and once with normal
NETN buffer to dissociate non-covalently bound ubiquitin.
Nickel-nitrilotriacetic acid pull-down under denaturing condi-
tion was performed as described previously [34]. GST-53BP1
fragments and His-BRCA11-304/His-BARD126-327 dimer were
purified from E. coli and co-incubated for 1 h at 30 °C for in vitro
ubiquitination assays, as described previously [20, 32].
ATM kinase assay
ATMwas immunoprecipitated from 293T cells with anti-ATM
antibody, and the kinase assay was performed as previously
described [33]. GST-53BP1 (residues 1–910 aa) fusion protein was
purified from E. coli and used as a substrate for ATM.
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